Ontario data show that vaccination makes little difference in terms of hospitalization and death rates for those below age 60
The report from Independent Researcher provides Evidence from open Ontario data
The following report - based on the official open data - was prepared and submitted to the Government of Canada by anonymous Canadian “Independent Researcher” in June 2022:
A Deeper Dive into the Publicly Available Ontario Data on COVID-19 Vaccination
A Report Prepared for Member of Parliament, by Independent Researcher, June 2022
It is available at this link (26-page PDF file) provided by Steve Kirsch.
The summary of results, conclusions and recommendations from the report are pasted below.
No response to it from any Canadian federal or provincial government authorities have been obtained yet, no mentioning of it in any official media.
Related article with comments and discussion is available from Steve Kirsch.
Summary of Results
A deeper dive into the publicly available data on vaccination from Public Health Ontario (PHO) and Public Health Agency of Canada (PHAC) provide the following answers to the questions posed.
1. Do the COVID-19 vaccines prevent infection and hospitalization? Full vaccination does not prevent infection and hospitalization. Even full vaccination with a booster does not prevent infection or hospitalization.
2. What are the trends in vaccinated and unvaccinated cases in the hospitals? In-mid April 2021, when less than 3% of Canadians were fully vaccinated, most of the cases in hospital were unvaccinated. In mid-January 2022, when 77% of Canadians were fully vaccinated, there were more vaccinated cases in hospital than unvaccinated cases.
3. Are there more vaccinated or unvaccinated cases in the ICU and hospitals at present (June 3, 2022)? There are 6 times more cases that are vaccinated versus unvaccinated currently in ICU and 5 times more vaccinated cases that are in the hospital compared to unvaccinated cases.
4. How does COVID-19 vaccination affect hospitalization rates for those 60 years and older? Lower hospitalization rates are seen for those 60 years and older that are vaccinated compared to those that are unvaccinated.
5. How does COVID-19 vaccination affect death rates for those 60 years and older? Lower death rates are seen for those 60 years and older that are vaccinated compared to those that are unvaccinated.
6. What is the impact of COVID-19 vaccination on hospitalization for various age groups? Vaccination is showing virtually no benefit to hospitalization rates among all age groups except for those 60 years of age and older. Vaccination shows benefit especially to those 70 years or older.
7. What is the impact of COVID-19 vaccination on death for various age groups? Vaccination is showing virtually no benefit to death rates among all age groups except for those 60 years of age and older. Vaccination shows benefit especially to those 70 years and older.
8. What are the most frequently reported adverse events associated with COVID-19 vaccines? There are numerous reported risks associated with the COVID-19 vaccines. Among 50 listed, the most frequently reported include paraesthesia, vaccination site pain, headache, pruritus, dyspnoea, and fatigue; while less frequently reported events include myocarditis, pericarditis; the least frequently reported include anaphylaxis, lip swelling, swollen tongue and dermatitis allergic.
9. What age groups report having adverse events from the COVID-19 vaccines? Those individuals between 18 and 69 years of age report having adverse events.
10. What gender reports having adverse events from the COVID-19 vaccines? Females disproportionately report having adverse events to the vaccines.
Conclusion
Although the scope of this report has been to examine the publicly available Ontario data, there are similar trends and patterns in other provinces as well as other countries. This has not been covered in this report due to time constraints and to ensure that the data analysis contained herein is as current, accurate and timely as possible. Nevertheless, due to the similarity of trends and patterns, numerous restrictions and bans have already been lifted internationally and provincially in the age of Omicron.
Given the statistical evidence provided in this report, the public health policy tools such as, mass vaccination campaigns, mandates, passports and travel restrictions need to be reevaluated for relevance in this phase of SARS-CoV-2. The abundance of evidence documented by Public Health Ontario (PHO), Public Health Agency of Canada (PHAC) and toptier scientific journals demonstrates that the vaccines do not prevent infection or hospitalization. The Ontario data show that vaccination currently makes little difference in terms of hospitalization and death rates for those below age 60. Additionally, since there are known risks of adverse events and unknown longterm effects, these must be considered in developing vaccine policies.
The empirical evidence investigated in this report from PHO and PHAC does not support continuing mass vaccination programs, mandates, passports and travel bans for all age groups. Rather, it may be prudent to utilize a more targeted and cost-effective approach focused on vaccinating the high-risk group, while factoring in an individual’s potential risk of vaccine-related adverse events.
Further Areas for Investigation
The following are some areas of on-going investigation for consideration. It is recommended that:
1. The exploratory data analysis conducted in this report be repeated every 3 months to monitor the evolving situation with regards to the COVID-19 vaccines.
2. The wealth of scientific literature be reviewed and monitored on an on-going basis to substantiate or challenge COVID-19 vaccination data findings.
3. The economic, social and psychological impacts of mass vaccination, vaccine mandates, passports and travel bans for the management of the pandemic be evaluated prior to setting or reinstating any vaccine policies.
4. The consequences of continuous boosters at regular intervals on the immune system be examined prior to adopting this strategy longterm.